Randomised clinical trial: the DPP-4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon-like peptide-1 plasma levels in healthy volunteers.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Protocol 1 (n = 10, 32.3 ± 3 years, 23.4 ± 0.7 kg/m2 ): 60 min after treatment, a nutrient drink (270 kcal) was infused intragastrically and intragastric pressure (IGP) was measured for 1 h.

Protocol 2 (n = 10, 24.3 ± 0.8 years, 22.3 ± 0.9 kg/m2 ): 60 min after treatment, HVs consumed one nutrient drink (300 kcal).

Thirty minutes thereafter, HVs ate ad libitum from a free-choice buffet for 30 min.

Why It Was Studied

Dipeptidyl peptidase-4 (DPP-4) inactivates glucagon-like peptide-1 (GLP-1).

Whether DPP-4 inhibition affects GLP-1 metabolism and/or food intake in humans remains unknown.

Who Took Part

The age groups tagged for this paper are young adults and adults, both men and women.

How the Study Was Run

In design terms this was a randomized, single-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

In this single-blind Glucagon study one party knew the assignments and the other did not.

Some participants received a placebo instead of Glucagon, giving a reference point.

What Was Measured

Topics PubMed links to this paper include Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Energy Intake, Glucagon-Like Peptide 1, Hypoglycemic Agents, Stomach and Vildagliptin.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Glucagon.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Alimentary pharmacology & therapeutics), a journal based in England.

More context: the Glucagon compound page, all human trials.